Cencora, Inc. (NYSE:COR) Chairman Sells $5,071,822.20 in Stock

Cencora, Inc. (NYSE:COR) Chairman Steven H. Collis sold 21,509 shares of Cencora stock in a transaction dated Tuesday, October 22nd. The stock was sold at an average price of $235.80, for a total transaction of $5,071,822.20. Following the completion of the sale, the chairman now directly owns 285,088 shares in the company, valued at approximately $67,223,750.40. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Cencora Trading Up 0.1 %

Shares of COR stock traded up $0.35 on Wednesday, hitting $234.52. 754,869 shares of the company’s stock traded hands, compared to its average volume of 1,415,712. The company has a debt-to-equity ratio of 3.93, a quick ratio of 0.55 and a current ratio of 0.89. The stock has a market capitalization of $46.78 billion, a price-to-earnings ratio of 25.62, a P/E/G ratio of 1.40 and a beta of 0.44. The company’s fifty day simple moving average is $232.32 and its 200 day simple moving average is $230.85. Cencora, Inc. has a one year low of $182.75 and a one year high of $247.66.

Cencora (NYSE:COR) last released its quarterly earnings data on Wednesday, July 31st. The company reported $3.34 EPS for the quarter, topping the consensus estimate of $3.18 by $0.16. Cencora had a return on equity of 266.60% and a net margin of 0.65%. The firm had revenue of $74.20 billion for the quarter, compared to the consensus estimate of $73.32 billion. During the same quarter in the previous year, the business earned $2.92 earnings per share. The company’s quarterly revenue was up 10.8% on a year-over-year basis. Equities analysts forecast that Cencora, Inc. will post 13.63 EPS for the current year.

Cencora Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, August 26th. Investors of record on Friday, August 9th were issued a dividend of $0.51 per share. The ex-dividend date was Friday, August 9th. This represents a $2.04 dividend on an annualized basis and a yield of 0.87%. Cencora’s dividend payout ratio is currently 22.32%.

Institutional Investors Weigh In On Cencora

A number of large investors have recently added to or reduced their stakes in the company. New Millennium Group LLC bought a new stake in shares of Cencora in the 2nd quarter worth approximately $26,000. TCTC Holdings LLC bought a new position in Cencora in the 1st quarter worth $29,000. TFO Wealth Partners LLC bought a new position in Cencora in the 1st quarter worth $30,000. MFA Wealth Advisors LLC bought a new stake in shares of Cencora during the 2nd quarter valued at about $30,000. Finally, LRI Investments LLC bought a new stake in shares of Cencora during the 1st quarter valued at about $31,000. Institutional investors own 97.52% of the company’s stock.

Analyst Upgrades and Downgrades

COR has been the subject of several research reports. Evercore ISI reduced their price objective on Cencora from $270.00 to $250.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th. StockNews.com downgraded shares of Cencora from a “strong-buy” rating to a “buy” rating in a report on Friday, September 20th. JPMorgan Chase & Co. lifted their target price on shares of Cencora from $280.00 to $287.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 21st. Robert W. Baird dropped their price target on shares of Cencora from $287.00 to $283.00 and set an “outperform” rating on the stock in a research note on Friday, September 6th. Finally, Wells Fargo & Company lifted their price target on Cencora from $236.00 to $249.00 and gave the company an “equal weight” rating in a research report on Thursday, August 1st. Three research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $259.44.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.